Terminated PHASE3 INTERVENTIONAL 2-arm NCT00137046

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

Efficacy and Safety of Exubera (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 1 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial

Sponsor: Pfizer

Conditions Diabetes Mellitus, Type 1

Interventions Inhaled Insulin Subcutaneous Insulin

Updated 8 times since 2017 Last updated: Feb 3, 2010 Started: May 31, 2002 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

See termination reason in detailed description.

Other terminated trials from Pfizer

See all terminations from Pfizer

Other Diabetes Mellitus, Type 1 trials with similar outcome

Browse all Diabetes Mellitus, Type 1 trials

This PHASE3 trial investigates Diabetes Mellitus, Type 1 and is currently terminated or withdrawn. Pfizer leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belo Horizonte, Brazil , Bethesda, United States , Burlington, United States , Butte, United States , Calgary, Canada , Campinas, Brazil , Capital Federal, Argentina , Chicago, United States , Coral Gables, United States , Curitiba, Brazil and 49 more locations